UK markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
8,795.00-19.00 (-0.22%)
At close: 4:35PM BST
Full screen
Previous close8,814.00
Open8,840.00
Bid8,779.00 x 0
Ask8,780.00 x 0
Day's range8,750.00 - 8,848.00
52-week range6,499.80 - 9,081.00
Volume1,422,485
Avg. volume3,355,203
Market cap136.247B
Beta (5Y monthly)0.18
PE ratio (TTM)41.86
EPS (TTM)210.10
Earnings date12 Nov 2021
Forward dividend & yield2.02 (2.30%)
Ex-dividend date12 Aug 2021
1y target est95.81
  • Editor's pick
    Yahoo Finance Video

    NIH Director on FDA ‘being careful’ in clearing Moderna vaccine for kids 12-17

    Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.

  • Motley Fool

    The Smartest Stocks to Buy With $200 Right Now

    Brokerages' race to the bottom in trading fees has been a breakthrough in helping to make investing less cumbersome to newcomers. While high commissions used to be a costly obstacle for new investors and discouraged some from investing altogether, that's now less of an issue. In fact, a recent study by discount broker Charles Schwab found that 15% of current U.S. investors bought their first shares just last year.

  • Business Wire

    IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer

    WILMINGTON, Del., October 15, 2021--Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. This novel dose and schedule